

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ZJ

中基長壽科學

ZHONG JI LONGEVITY SCIENCE

Zhong Ji Longevity Science Group Limited

中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

**FURTHER ANNOUNCEMENT
DELAY IN PUBLICATION OF AUDITED RESULTS
ANNOUNCEMENT AND DESPATCH OF
ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2021**

This announcement is made by the board (the “**Board**”) of directors (“**Directors**”) of Zhong Ji Longevity Science Group Limited (the “**Company**”) together with its subsidiaries, the “**Group**”) to provide certain updates to its shareholders and potential investors relating to the publication of the audited annual results (the “**2021 Annual Results**”) and the despatch of the annual report (the “**2021 Annual Report**”) for the year ended 31 December 2021.

References are made to (i) the announcement of the Company dated 30 March 2022 in relation to, among others, the delay in publication of the 2021 Annual Results; (ii) the announcement of the Company dated 31 March 2022 in relation to the unaudited annual results of the Company for the year ended 31 December 2021; and (iii) the announcement of the Company dated 29 April 2022 in relation to, among others, further delay in publication of the 2021 Annual Results and delay in despatch of the 2021 Annual Report (the “**Delay Announcements**”). Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Delay Announcements.

As disclosed in the Delay Announcements, the Company's operating subsidiaries in Beijing and Shanghai constitute a material part of the Group's consolidated financial position and operating results in terms of asset size and income scale, including two major financial assets of the Group. The Audit Process for the 2021 Annual Results have been adversely affected by the Latest Outbreak and the Measures in Beijing and Shanghai. In particular, the staffs in Beijing and Shanghai could not travel to the offices due to the Measures but certain documents of the Group, including certain books and records that were required to conduct the Audit Process, were retained in the office premises and could not be accessed until the relevant Measures lifts or complied with. Due to the Measures, the Group also encountered delay in retrieving certain documents from the relevant government authorities. Hence, only limited information were provided to the auditors and the auditors had to adopt alternative procedures, which required additional time for completing the Audit Process. In addition, as certain banks, customers and suppliers of the Group were also located in Beijing and Shanghai, the Group consider that the Measures had also delayed the banks, customers and suppliers in responding to the audit confirmations and hence the auditors were still yet to receive sufficient audit confirmations. The delay in responses from the customers also hinder the process in compiling the valuation reports on, among others, trade receivables and expected credit loss. Given the above and the additional time required for completing the alternative procedures, KTC considers that the Audit Process is expected to complete on or around 27 May 2022 based on KTC's preliminary assessment and the assumption that the Measure will gradually lift in May 2022. Based on this assumption, it is expected that fieldwork required for audit will complete on around 19 May 2022 and the annual audit work will be completed by 24 May 2022. It is expected that the audited 2021 Annual Results will be published on 27 May 2022 and the 2021 Annual Report will be despatch to shareholders on or before 30 May 2022.

An application had been made to the Stock Exchange for the approval for the delay in publication of the 2021 Annual Report, the Stock Exchange has granted to the Company a waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rules on the basis that the Company will despatch the 2021 Annual Report on or before 30 May 2022. The Company will keep the shareholders and potential investors informed of the latest progress of the 2021 Annual Results and 2021 Annual Report and will make further announcement as and when appropriate in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman

Hong Kong, 17 May 2022

As at the date of this announcement, the Directors are:

Executive Directors

Mr. Yan Li (*Chairman*)
Mr. Yan Yifan (*Chief Executive Officer*)
Mr. Li Xiaoshuang
Ms. Cao Xie Qiong

Independent non-executive Directors

Mr. Lee See Barry
Mr. Wang Ning
Prof. Huang Cibo

Non-executive Directors

Dr. He Yiwu
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.